21.09
-0.05 (-0.24%)
| 前收盘价格 | 21.14 |
| 成交量 | 524,940 |
| 预期市盈率 (P/E Forward) | 18.34 |
| 价格/销量 (P/S) | 1.39 |
| 股市价格/股市净资产 (P/B) | 1.17 |
| 52周波幅 |
| 营业毛利率 | -7.50% |
| 营业利益率 (TTM) | -5.36% |
| 稀释每股收益 (EPS TTM) | -1.02 |
| 季度收入增长率 (YOY) | 3.50% |
| 总债务/股东权益 (D/E MRQ) | 75.07% |
| 流动比率 (MRQ) | 1.56 |
| 营业现金流 (OCF TTM) | 166.00 M |
| 杠杆自由现金流 (LFCF TTM) | 69.00 M |
| 资产报酬率 (ROA TTM) | 0.61% |
| 股东权益报酬率 (ROE TTM) | -5.36% |
新闻情绪
-
Bausch + Lomb (BLCO) Stock Still Looks Undervalued Despite Its 35% Run
5天之前, 10:27PM
-
Best Growth Stocks to Buy for November 13th
5天之前, 1:25AM
-
Best Growth Stocks to Buy for November 11th
11 Nov, 1:44AM
AIStockmoo 评分
| 价值 30% | 0.0 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 负债低。盈利能力弱。现金流为正。 参考 | |
| 资本回报 参考 | NA |
| 时机 30% | 3.6 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年没有明确趋势。股价接近52周高点。 参考 | |
| 上升趋势:股价位于均线之上,均线向上。股价已大幅高于均线。上涨日成交量较大。 参考 | |
| K线形态 参考 | NA |
| 高于中期趋势线。 参考 | |
| 市场情绪 20% | 0.7 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻大多正面。 参考 | |
| 聪明钱 20% | -0.5 |
| 内部交易活动 参考 | NA |
| 机构在最新13F申报中净-0.28%的股份:60家增持,35家减持(截至30 Sep 2026的季度)。 参考 | |
| 市场和行业状况中性。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现优于大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 股价高于其52周平均水平。 参考 | |
| 短、中、长期趋势均向上。短期动能上升。 参考 | |
| 股价接近阻力位。 参考 | |
| 最终评分 | 1.34 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 混合的 | 混合的 |
| Medical Instruments & Supplies (全球的) | 混合的 | 混合的 | |
| 股票 | Bausch + Lomb Corporation | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| BLCO | - | - | - | 1.17 |
| RMD | - | 1.08% | - | 5.66 |
| BDX | - | 2.20% | - | 2.41 |
| WST | - | 0.37% | - | 9.67 |
| ALC | - | 0.49% | - | 1.64 |
| STVN | - | 0.30% | - | 2.39 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Mid Core |
| 内部持股比例 | 88.13% |
| 机构持股比例 | 10.97% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Caspian Capital Lp | 30 Jun 2026 | 1,999,043 |
| Glenview Capital Management, Llc | 30 Jun 2026 | 1,918,148 |
| Clark Estates Inc/Ny | 30 Sep 2026 | 881,000 |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 10.66%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 60 | 5,333,667 |
| 减持 | 35 | 5,694,076 |
| 新建仓 | 24 | 1,736,083 |
| 清仓 | 9 | 2,368,991 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
| 日期 | 类型 | 细节 |
|---|---|---|
| 14 Nov 2026 | Yahoo Finance |
Bausch + Lomb (BLCO) Following Its Rally Is Fair Value Still In Sight
Bausch + Lomb (BLCO) has been drawing attention after recent trading, with the share price last closing at US$21.09. The move sits against a recent pattern of mixed short term and longer term returns. Over the past month, Bausch + Lomb has seen a sharp shift in momentum, with a 31.48% 30 day share… |
| 13 Nov 2026 | Yahoo Finance |
Bausch + Lomb (BLCO) Stock Still Looks Undervalued Despite Its 35% Run
Bausch + Lomb shares have moved higher in recent months, which puts a sharper spotlight on whether the current US$21.09 price lines up with the cash flows the business can realistically generate. After a solid stretch for the stock, the key issue for anyone looking at Bausch + Lomb today is how… |
| 13 Nov 2026 | Yahoo Finance |
Best Growth Stocks to Buy for November 13th
BLCO, VLO, and HAS it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 13, 2026… |
| 11 Nov 2026 | Yahoo Finance |
Best Growth Stocks to Buy for November 11th
BLCO, VLO, and HAS it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 11, 2026… |
| 06 Nov 2026 | Yahoo Finance |
Zacks.com featured highlights include Repsol, Bausch + Lomb, DMC Global, Universal Logistics and Methanex
Repsol, Bausch + Lomb and three other stocks show strong relative price strength, rising earnings estimates and potential for further gains. |
| 05 Nov 2026 | Yahoo Finance |
Are You Looking for a Top Momentum Pick? Why Bausch + Lomb (BLCO) is a Great Choice
Does Bausch + Lomb (BLCO) have what it takes to be a top stock pick for momentum investors? Let's find out. |
| 04 Nov 2026 | Yahoo Finance |
Bausch + Lomb: 3 Key Takeaways for Long-Term Investors
Premium product adoption is lifting margins faster than revenue growth, a sign of pricing power in a competitive market. |
| 04 Nov 2026 | Yahoo Finance |
Why Bausch + Lomb (BLCO) Might be Well Poised for a Surge
Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
| 03 Nov 2026 | Yahoo Finance |
BLCO vs. HQY: Which Stock Is the Better Value Option?
BLCO vs. HQY: Which Stock Is the Better Value Option? |
技术形态 中期
AI 技术分析
投资组合